SoundHound AI Eyes Profitability Path as Stock Trades Below $8

The Motley FoolThe Motley Fool
|||1 min read
Key Takeaway

SoundHound AI stock down 65% to below $8 amid $109M operating losses. Company targets profitability in 2026 while expanding voice AI platform across industries.

SoundHound AI Eyes Profitability Path as Stock Trades Below $8

SoundHound AI's stock has declined 65% from its 52-week peak, currently trading below $8 per share as the company continues to navigate a path toward profitability. The voice artificial intelligence firm reported third-quarter 2025 revenue of $42 million against operating losses of $109.3 million, reflecting the investment phase typical of growth-stage technology companies expanding their market presence.

The company's voice AI platform has gained traction across multiple verticals, with deployments in restaurant operations, automotive systems, and consumer smart devices. Management has identified a $140 billion addressable market opportunity and projects the company can sustain high growth rates while approaching profitability during 2026, a transition that could signal a turning point for investor sentiment.

At current valuation levels, investors are weighing the company's established technology footprint and market expansion potential against its substantial near-term losses and execution risks. The projected shift toward profitability next year represents a key metric that market participants will monitor as evidence of the business model's viability at scale.

Source: The Motley Fool

Back to newsPublished Feb 15

Related Coverage

GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR
GlobeNewswire Inc.

Pomerantz Files Securities Fraud Suit Against $INO Over FDA Approval Misstatements

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

INO